Farmak, a Ukrainian pharmaceutical company, announced the acquisition of Symphar, a Polish company, becoming a 100% owner of this pharmaceutical company. This acquisition is a part of the international expansion strategy Farmak 2.0: From Local Success to Global Success.

According to the company's press release, the transaction will increase Farmak's market share and strengthen its position in the diabetes, nervous system and women's health segments in the European Union.

"This transaction is the result of careful preparation and evaluation of various options in the Polish market. The acquired business fully complies with the legal requirements and high ethical and corporate standards of Farmak. The transaction was concluded after fulfillment of the terms of the agreement and the necessary regulatory procedures," the press release said.

Investment banking company FinPoint acted as Farmak's exclusive financial advisor in this acquisition. The seller's financial advisor was Swiss Merchant Corporation SA, a Swiss investment advisory company.